Student Comment: Not Really a Battle of the Sexes: Women’s Health Agenda Advocates Global Equality in Medical Research Trials and Drug Administration by Beltran, Margery R.
University of Baltimore Journal of International Law
Volume 4
Issue 2




Student Comment: Not Really a Battle of the
Sexes: Women’s Health Agenda Advocates Global
Equality in Medical Research Trials and Drug
Administration
Margery R. Beltran
University of Baltimore, margery.beltran@ubalt.edu
Follow this and additional works at: http://scholarworks.law.ubalt.edu/ubjil
Part of the Health Law and Policy Commons, Human Rights Law Commons, International Law
Commons, and the Law and Gender Commons
This Article is brought to you for free and open access by ScholarWorks@University of Baltimore School of Law. It has been accepted for inclusion in
University of Baltimore Journal of International Law by an authorized editor of ScholarWorks@University of Baltimore School of Law. For more
information, please contact snolan@ubalt.edu.
Recommended Citation
Beltran, Margery R. (2016) "Student Comment: Not Really a Battle of the Sexes: Women’s Health Agenda Advocates Global Equality





Not Really a Battle of the Sexes: Women’s Health 
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Trials and Drug Administration 
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ABSTRACT: The New Women’s Health Agenda seeks to close the 
discriminatory gap between men’s and women’s medical treatment 
around the world.  Often, women’s reproductive issues are the focus 
of medical studies in which women are involved; however, chronic 
diseases are quickly becoming a high health risk for the female popu-
lation around the world.  This comment explores the past, present, 
and future of women’s global health.  Throughout history, women 
have been prevented from participating in clinical trials for reproduc-
tive protection reasons.  The problem arises after men have success-
fully responded to treatment because the medication is then adminis-
tered to both men and women.  Women are still facing numerous 
challenges in regards to proper healthcare today.  Women today are 
experiencing an increase in mental health diseases and chronic dis-
eases such as heart disease, autoimmune diseases, and HIV/AIDS.  
Women of color and of low socioeconomic status also face their own 
unique challenges.  This comment argues importance of a global 
healthcare system in which men and women are treated as biological-
ly different, but socially and psychologically equal.  
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I.  Introduction 
 Between lifestyle changes and the shift to a longer-living popu-
lation, women’s health, both reproductive and non-reproductive, has 
become an issue on the rise throughout the field of public health.1  
“The world still focuses very much maternal health and, more recent-
ly, family planning, which definitely reflect critical needs; [however], 
the predominant view today is of women as reproductive beings, 
which leads to neglect of women’s health in other stages of life,” ex-
plained Ana Langer, Professor at the Harvard T.H. Chan School of 
Public Health.2  The New Women’s Health Agenda (“Agenda”) aims 
to address what Langer calls the “double burden of disease among 
women” in order to promote health to women of all ages around the 
world.3 
 The Agenda’s double burden of disease integrates two scopes 
of study in women’s health.4  The first burden and most commonly 
studied are the problems that still exist in the realm of reproductive 
health, infectious diseases, gender-based violence, and malnutrition.5  
The second, and more recently emerging, is the epidemic of chronic 
diseases.6  There is a drastic inequality in government focus on wom-
en’s reproductive and non-reproductive health around the world.7 
 The Agenda is concerned about the rise of chronic diseases and 
the lack of preparedness, especially in low to middle socioeconomic 
status countries.8  Langer also notes that chronic diseases and repro-
ductive health problems are more common in the low to middle soci-
oeconomic class countries, primarily in Europe and Africa.9   
 
 1. Fiona Fleck, The New Women’s Health Agenda, 91 BULL. WORLD HEALTH ORG. 628 
(2013).  Ana Langer is an advocate for women’s health on the global level and has 
served on the boards for multiple global health organizations over the past 25 years.  
She is at the forefront of the Women and Health Initiative at the Harvard School of 
Public Health. 
 2. Fleck, supra note 1. 
 3. Id. 
 4. Id. 
 5. Id. 
 6. Id. 
 7. Id. 
 8. Fleck, supra note 1 (“It seems that donors are not prepared to invest in the prevention, 
detection and treatment of chronic diseases affecting women unless more progress is 
made in the unfinished agenda of reproductive health.”). 
 9. See generally id.  
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 This comment explores the discrimination towards women in 
medical research and treatment throughout the world while develop-
ing a clearer understanding of the Agenda’s objectives.  Through a 
combination of modern medical research analysis and a historical ex-
amination of gender discrimination in medical testing, this comment 
argues that the Agenda is a necessity in the field of global health.  
The Agenda, which was created in 2010 at the Harvard School of 
Public Health, is quickly gaining recognition among global medical 
researchers and academics.10  The Agenda aims to improve the out-
look of women’s health research and treatment in order to bring 
equality to women in their treatment for chronic diseases and repro-
ductive health.11   
II. Historical Discrimination: A Timeline of Women’s Treatment 
Gender Bias and Discrimination 
 In the field of medicine, women fall victim to sex discrimina-
tion.12  However, traditional treatment of women has not been with-
out its own rationale.13  According to Langer, there are valid concerns 
in regard to including women in clinical trials, but that these concerns 
should not bar women from participating in the trials: 
There is evidence that discrepancies exist between men and 
women in terms of the attention they receive for the problems they 
have in common…Women are not recruited to trials for the testing of 
drugs for chronic diseases that, once approved, are used by women.   
Women are often not considered “stable enough” to participate in 
such trials because of their menstrual cycles, because they may be-
come pregnant during the trial and because they may be breastfeed-
ing, which could incur risks for the baby.  Therefore, women are ex-
cluded from many trials and as a result don’t get proper treatment 
later.14 
 
 10. Id. at 629. 
 11. Id. 
 12. Anita Holdcroft, Gender Bias in Research: How Does it Affect Evidence Based Medi-
cine?, 100 J. ROYAL SOC’Y OF MED. 2 (2007). 
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 Clinical research demonstrates gender bias in a number of 
ways.15  A key issue in women’s discrimination is the field’s tenden-
cy to apply the research collected from male-dominated clinical trials 
to women’s clinical treatment.16  While the rationale to protect the re-
productive anatomy of women when collecting research is under-
standable, that rationale is counterintuitive on the macro-level goal of 
improving the overall health of women.17  There is a huge discrepan-
cy between clinical trials and treatment.18  Women must forego test-
ing of a drug, but if it proves successful for men, it is then prescribed 
to women.19 
 Anita Holdcroft provides the example of gender differences in 
the treatment of coronary artery disease between men and women in 
which male studies on heart disease are provided far more funding 
than women.20  Holdcroft found coronary artery disease research 
funding is far more generous to studies for males; however, the risk 
of the disease is far higher for women.21  Women have a much higher 
chance of dying from coronary artery disease than men.22  Therefore, 
there should be more studies focused on either just women or the dif-
ferences between men and women’s symptoms and reactions to med-
ication treating coronary artery disease.23 
 The same result occurs across the medical field.  For instance, 
research strongly suggests women have stronger immune systems 
than men,24 thus women have a naturally higher prevention of dis-
ease.25  Unfortunately, this also leaves women far more likely to de-
 
 14. Id. at 629; see also Holdcroft, supra note 12 (“The evidence bases of medicine may be 
fundamentally flawed because there is an ongoing failure of research tools to include 
sex differences in study design and analysis.  The supporting bias which this method-
ology maintains creates a situation where guidelines based on the study of one sex may 
be generalized and applied to both.”). 
 15. Holdcroft, supra note 12. 
 16. Fleck, supra note 1. 
 17. Holdcroft, supra note 12. 
 18. Id. 
 19. Id. 
 20. Id. 
 21. Id. 
 22. Id. 
 23. See generally Holdcraft, supra note 12. 
 24. Donna E. Shalala, Women Get Heart Disease Too: A Brief History of Gender Discrim-
ination in Medical Research, 10 COLUM. J. GENDER & L. 57, 59 (2000). 
 25. Id. 
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velop autoimmune diseases such as multiple sclerosis, lupus, sclero-
derma, and rheumatoid arthritis—all of which are unrelated to repro-
ductive health issues.26  The Agenda can help broaden the narrow fo-
cus of the traditional reproductive health narrative to include chronic 
diseases.27 
 In the past two decades, the U.S. National Institute of Health 
(hereinafter “NIH”) has begun to acknowledge this lack of attention 
to women’s specific health problems.28  In 1994, NIH implemented a 
set of guidelines to ensure trial drugs would be tested on a wider 
range of patients who would ultimately use the medication or thera-
py.29  Before the implementation of this policy, women were often 
excluded from early stage drug trials as a precautionary measure.30  
NIH decided that this was a substantial issue because there was little 
information regarding how the drugs would affect women—the same 
battle being fought by the Agenda.31   
 By 1997, 94% of NIH research grant proposals included wom-
en as subjects.32  But, almost twenty years since 1997, there is still a 
discrepancy in research enrollment of men and women.  To better 
understand the continued discriminatory research practices, it is im-
perative to examine the historical context of gender differences in 
medical research.  Since the global initiative grew out of primarily 
U.S. policy, an examination of U.S. policy changes will be conducted 
henceforth to understand how the Agenda has shaped the internation-
al landscape regarding medical research for women. 
 
 26. Id. 
 27. Fleck, supra note 1. 
 28. Shalala, supra note 24. 
 29. Id. 
 30. Id. Holdcroft noted in 2005, eight out of ten prescription drugs were withdrawn from 
the U.S. prescription pharmaceuticals market due to their negative effects on women’s 
health.  Not only is administering drugs not tested on women a dangerous gamble to 
women’s health, but it is also an extremely wasteful use of resources.  Holdcroft, su-
pra note 12. 
 31. Holdcroft, supra note 12. 
 32. Id. 
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a. A U.S. Historical Exploration of Women’s Medical 
Research and Treatment 
i. Guinea Pigs: Early 19th Century Clinical Trials 
In the early 19th century, African-American slave women were 
the primary test subjects in clinical trials.33  These tests were con-
ducted at a time when anesthesia was non-existent.34  Physicians at 
this time would repeat the heinous and inhumane experiments on the-
se women in order to find the best forms of treatment.35  Moving to 
the 1900s, researchers around the world shifted to using institutional-
ized populations, including mental health patients, prisoners, and 
concentration camp victims.36 
 By 1949, the abuses to the institutionalized had been revealed 
to the global public and there was a movement formed to protect hu-
mans from unjust experimentation.  This eventually culminated in the 
Nuremburg Code.37  The code “set out ethical and legal standards for 
the conduct of human research aimed at protecting human research 
subjects from the types of experimentation practices used by the Na-
zis in World War II.”38  According to Rothenberg, the U.S. was still 
slow to develop their clinical trial regulations after the code was im-
plemented.39 
ii. Trial and Error: Policy Shifts in the U.S. Since the Mid-1900s 
 As previously stated, there has been logical rationale behind 
avoiding women’s inclusion in new drug trial treatment.40  Research-
ers do not want to be liable for potentially harming a woman’s fertili-
ty or an unborn child.41  At the most primal level, the human race, 
like all other animals, wants to preserve its species.42  The Agenda 
 
 33. Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Wom-
en’s Health Care, 32 HOUS. L. REV. 1201, 1220 (1996). 
 34. Id. 
 35. Id. 
 36. Id. 
 37. Id. 
 38. Id. 
 39. Rothenberg, supra note 33. Rothenburg believes that the U.S. changes in policy are 
primarily attributed to the Thalidomide tragedy in the 1960s.  Id. 
 40. See supra Section 1. 
 41. Fleck, supra note 1. 
 42. See generally id. 
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does not criticize the protection and preservation of reproductive 
health of women; it works to find ways to preserve and protect fe-
male reproduction health issues, while also ensuring proper treatment 
for women with non-reproductive health problems.43 
 There was a great deal of hesitance in the field of medicine to 
treat women with experimental drugs.44  Though NIH’s initiative was 
not implemented until 1994, there was a small increase in the late 
1980s in including women in clinical trials.45  Sarah Keitt attributes 
the hesitance to include women to two distinct reasons: the first, be-
ing a general neglect to women throughout history; the second, being 
the Thalidomide tragedy in the 1960s,46 which caused medical re-
searchers to be more aware of their effects on unborn children.47  The 
Thalidomide tragedy sparked stricter legislative regulation for wom-
en as test subjects in the 1960s and 1970s.48 Keitt believes that did far 
more harm than good.49   
 Prior to this 1980’s shift of female inclusion, researchers fell 
into one of two categories with regard to women in clinical trials; this 
categorization is also attributed to women’s involvement in testing at 
the time.50  Some researchers assumed women to simply be smaller 
versions of men and thus viewed women as unnecessary test sub-
 
 43. See generally id. 
 44. See generally Sarah K. Keitt, Sex & Gender: The Politics, Policy, and Practice of 
Medical Research, 3 YALE J. HEALTH POL’Y L. & ETHICS 253 (2003). 
 45. Id. 
 46. “In 1962, the Kefauver-Harris Amendment, perhaps the most important piece of legis-
lation regulating the conduct of clinical trials, was passed with the purpose of protect-
ing children, pregnant women, and fetuses.  The Kefauver-Harris amendment required 
drug manufacturers to demonstrate that new drugs were safe and effective via adequate 
and well-controlled clinical trials. This legislation was passed in response to the thou-
sands of babies with severely deformed limbs as a result of utero exposure to Thalid-
omide (used to prevent morning sickness).  Later, during the early 1970s, research re-
vealed the daughters of women who took diethylstilbestrol during pregnancy had an 
increased risk of vaginal cancer. In 1977, the [FDA] responded to these events by issu-
ing guidelines that required women of childbearing potential to be excluded from 
[drug trials until data from animal studies regarding development disturbances in em-
bryonic or fetal was collected].  The only exception to these guidelines was for drugs 
used in treatment of life-threatening or serious diseases.”  Id. at 255. 
 47. Id. at 253. 
 48. Id. 
 49. Keitt, supra note 44. 
 50. Id. at 254. 
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jects.51  The other group viewed women’s biology as too complicated 
to study due to their hormonal cycles.52  The assumption of hormone 
complications draws a question of irony in that researchers were pre-
venting women from inclusion in medical trials for medication creat-
ed to treat women.53  Critics have since pointed out that drugs tested 
on men only, were also being prescribed to women even though the 
researchers conducting the trials fully recognized that fluctuations of 
hormones affect how a woman reacts to certain kinds of drugs.54  The 
risks of some of those prescriptions administered could have been 
very dangerous, and medical researchers at the time had very little 
data on what sort of reactions women could have.55 
 By 1983, the then-Assistant for Secretary of Health, Dr. Ed-
ward Brandt noticed a distressing pattern in medical research.56  
Brandt found that there was a plethora of information regarding men-
opause, pregnancy, and menstruation, but hardly any information on 
chronic illnesses that affect both men and women, namely heart dis-
ease.57  To remedy this problem, Brandt formed a national task force 
dedicated to analyzing women’s health issues.58   
 In 1985, the task force concluded that the lack of research on 
women’s non-reproductive health issues was negatively affecting the 
overall healthcare of women.59  The task force’s findings prompted 
the official NIH guidelines for inclusion of women, particularly 
women of childbearing potential, in federally funded clinical re-
search.60  Despite the NIH’s efforts for female inclusion, advocates 
for women’s health and the task force found that since the inclusion 
guidelines were not “enforced,” trials were still being conducted in 
the same way they were prior to the implementation of the guide-
lines.61 
 
 51. Id. 
 52. Id. 
 53. Shalala, supra note 24. 
 54. Id. 
 55. See generally Shalala, supra note 24. 
 56. Keitt, supra note 44. 
 57. Id. at 255-56. 
 58. Id. at 256. 
 59. Keitt, supra note 44, at 256. 
 60. Id. 
 61. Id. (“Women were still routinely excluded from clinical trials.”).  
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iii. The 1990s and the Society for Women’s Health Research 
 In 1990, the increasingly frustrated and concerned advocates 
for women’s health formed the Society for Women’s Health Re-
search (hereinafter “Society”).62  The Society sought to enforce the 
NIH clinical trial rules by placing pressure on the U.S. Congress to 
involve the General Accounting Office.63   
 After a great deal of investigation, the General Accounting Of-
fice found that the “NIH policy had not been well communicated or 
understood within NIH or the research community, was applied in-
consistently across institutes, and only applied optional research.  
NIH had also done little to encourage the analysis of studying sex dif-
ferences in data.”64  The report found that only 13% of the NIH budg-
et was allocated to women’s health research.65  The findings sparked 
a serious shift in women’s health.66  Following the findings, research-
ers were informed by the government that they would be held ac-
countable if they did not follow the NIH guidelines and that policies 
had to be treated like mandates.67 
 As the 1990s progressed, various new proposals and bills be-
gan to develop to protect women’s treatment.68  By 1995, the FDA 
had also proposed regulation requirements to include safety and effi-
cacy data by gender.69  All the changes in the 1990’s provided more 
accessible opportunities for women.70 By the 2000s, women were 
proportionally represented in clinical trials with the exception of 
pregnant women.71 
 Fortunately, abusive medical treatment is no longer an ac-
ceptable practice to any person, regardless of biological sex. There 
are still many discrepancies between the way men and women are 
treated in clinical trials.  The Agenda seeks equality in the quality of 
 
 62. Id. 
 63. Id. 
 64. Id. 
 65. Caroline W. Jacobus, Legislative Responses to Discrimination in Women’s Health 
Care: A Report Prepared for the Commission to Study Sex Discrimination in the Stat-
utes, 16 WOMEN’S RTS. L. REP. 153, 174 (1995). 
 66. Keitt, supra note 44, at 257. 
 67. Keitt, supra note 44, at 257. 
 68. See generally Shalala, supra note 24. 
 69. See generally Shalala, supra note 24. 
 70. Keitt, supra note 44, at 258. 
 71. Id. 
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treatment towards women in medical trials because modern medicine 
is still discriminatory towards women. 
III. Testing Positive for Unequal Treatment Towards Women in 
Modern Medicine 
a. Biopsychosocial Differences: What really needs to be 
addressed? 
i. Attitudes and Behaviors in the Healthcare Facility 
Women tend to receive more direct health care over their life 
span.72  This is primarily attributed to their reproductive health needs 
and their longer life expectancy.73  In one study comparing the gen-
eral treatment of men versus women in healthcare facilities, research-
ers concluded, “women’s health care tends to be comprised of drug 
prescriptions and routine checks whereas major diagnostic and thera-
peutic interventions are more frequently performed on men.”74 
In the past twenty to thirty years, physicians have changed their 
notion about how women experience symptoms of illnesses and dis-
eases.75  It was often assumed, throughout the field, that men and 
women experience symptoms the same way.76  This could contribute 
to the assumption that women could be prescribed the same treat-
ments as men.77 
 According to Jacobus, in 1995, men were 6.5 times more likely 
to be tested for common chronic diseases.78  “Women’s ailments are 
more likely to be attributed to emotional rather than physical caus-
es.”79  According to recent social demographic research conducted by 
University of Michigan, both men and women develop the same 
types of illnesses.80  The key differences arise in the frequency of 
 
 72. Jacobus, supra note 65, at 174. 
 73. Id. 
 74. Jacobus, supra note 65, at 174. 
 75. Id. 
 76. Id. 
 77. Id. 
 78. Id. 
 79. Id. 
 80. Megan Veith, Note, The Continuing Gender-Health Divide: A Discussion of Free 
Choice, Gender Discrimination, and Gender Theory as Applied to the Affordable Care 
Act, 21 GEO. J. POVERTY L. & POL’Y 341, 345 (2014). 
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those illnesses and the “pace of death” among the sexes.81  Thus, both 
should be treated according to their biological needs.82  Gender-
specific medicine positively impacts both men and women:  
Although [the modern] field of medicine originated from femi-
nist critiques of the current health care system’s treatment of women 
in the past, gender-specific medicine strives to help both women and 
men, especially concerning gender difference in disease susceptibility 
and lifespan.  Gender-specific medicine is important because it seeks 
to recognize the differences between men and women’s health, while 
also ensuring that both genders are equally represented in medicine.83 
 The issue at hand is not to advocate for a healthcare system in 
which women take precedence over men in clinical trials and treat-
ment.  The goal should be achieving just and fair treatment of both 
men and women in medical research to ensure a healthier future for 
all persons.  Historically, research on women’s health is far less de-
veloped than that of men and thus, there may need to be an increased 
focus on women’s health issues in the near future.84   
ii. Women of Color in Medicine 
A subcategory of disparities among women’s health is the treat-
ment of women of color in  
the healthcare system, especially with regard to clinical trials.  
The health concerns of women of color, who compromise a crucial 
percentage of the world’s population, are in need of attention from 
researchers.85 
Although various programs and policies throughout the world 
have begun to mandate the inclusion of women in clinical trials, 
many of the advancements fail to provide benefits to women of col-
 
 81. Veith, supra note 80. 
 82. Id. 
 83. Id. at 344.  In regards to the modern involvement of the U.S. in women’s health 
movements, “The gender-specific medicine movement has greatly benefitted women, 
who have been the focus of much of the new scientific studies and research of the last 
few decades.  Thus, it may come to a surprise that the [Affordable Care Act] includes 
more female-specific benefits that male-specific benefits.”  Id. at 355. 
 84. See generally Keitt, supra note 44. 
 85. See generally Lisa C. Ikemoto, Deconstructing the Image Repertoire of Women of 
Color: In the Shadow of Race: Women of Color in Health Disparities Policy, 39 U.C. 
DAVIS L. REV. 1023 (2006). 
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or.86  “[T]he core failure – inattention to the intersections of catego-
ries used for social ordering – leaves the particular ways that racial-
ized patriarchy allocates health risks to women of color out of sight 
and out of mind.”87  Lisa Ikemoto argues that in the past fifty years, 
racism and patriarchy have been successfully addressed;88 however, 
racism and patriarchy issues continue to act as completely separate 
entities from initiatives to promote the health needs of women of col-
or.89 
As social health disparities continue to be acknowledged, social 
scientists are gathering data on how biopsychosocial factors affect a 
person’s health treatment.90  Researchers found that biological race, 
socioeconomic status, and general lifestyle habits are the key factors 
fueling all health disparities and differences in mortality rates among 
races.91   
According to Ikemoto, hardly any research has been conducted 
on the specific disparities and needs for women of color92 because 
they were assumed to be a subcategory of the already studied race 
disparities and thus need no extra examination.93  Ikemoto raises her 
concern that researchers are only addressing the problem in a fashion 
that is far too narrow because they are only looking at the factor of 
race, while disregarding gender.94 Ikemoto fears that “the narrowing 
scope of the health disparities inquiry threatens to constrain the un-
derstanding of health, as well as to push the health needs of women 
of color and others back into the shadows.”95  The world is quickly 
recognizing health disparities among racial groups.    
iii. The Flaws of Structuralism Research 
In regards to the research collected and analyzed about race, 
Ikemoto also criticizes the primary research and implications of the 
 
 86. Ikemoto, supra note 85, at 1025. 
 87. Id. 
 88. Id. at 1026. 
 89. Id. 
 90. Id. 
 91. Id. 
 92. Ikemoto, supra note 85, at 1026. 
 93. Id. 
 94. Id. 
 95. Id. 
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structuralist school of thought.96  In other words, the research is col-
lected under a framework that focuses on organizational structures in 
society, and in this case, how those structures affect health outcomes 
among racial classes.97 
Structuralism analyzes how large societal influences, such as 
governments or global policy organizations, affect the treatment of 
humans.98  Leadership organization’s treatment towards groups of 
people, regardless of whether they are subtle or not, can have a great 
deal of effect on stereotypes and the way people react to one anoth-
er.99  According to Ikemoto, structuralism can be one of the most suc-
cessful ways to analyze governing organizations and their effects on 
populations, but it should not be the only approach used.100  This the-
ory can provide insight as to what sort of policy changes or legal in-
terventions should be implemented.101  
Structuralism is often the theory of choice because it assumes 
racism is perpetuated through the operation of greater institutions.102  
Under the structuralist theory, implementing strict programs and 
providing cross-cultural training would eventually lead to the elimi-
nation of racism in healthcare.103  Application of this theory in pro-
gram development can identify the changes in tangible practices, 
which has the possibility of greatly improving the treatment of the 
disparaged.104  The problem arises when the changes in practice do 
not adapt with the fluid changes in ideology.105  According to Ikemo-
to, it is not the best nor is it the only theory in addressing disparities 
to different races and women,106 because “racism and patriarchy per-
sist even as their forms change.  As new practices and standards 
 
 96. Id. 
 97. Id. 
 98. See generally Ikemoto, supra note 85, at 1027. 
 99. See generally id. 
 100. Ikemoto, supra note 85, at 1027-28. 
 101. Id. (“While structuralist analysis is good at identifying opportunities for legal interven-
tion. An exclusive focus on health care organizations and practices fails to fully ac-
count for how orders or power formed by racialized patriarchy can persist despite the 
dismantling of specific institutional structures and practices.”). 
 102. Id. at 1048-49. 
 103. Id. at 1049. 
 104. Id. at 1050. 
 105. Id. 
 106. Ikemoto, supra note 85, at 1050. 
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emerge, ideology flows in and provides context.”107  As the fluidity 
and adaptation of racial and patriarchal issues develop, the structural-
ism theory is able to narrow down what the new challenges are to so-
ciety and how they were shaped.108 
 Instead, Ikemoto recommends critically analyzing cultural 
formation; while structuralism theory should continue to be used, 
Ikemoto believes that implementing the added critical analysis will 
greatly improve the health disparities of women of color.109  Critical 
analysis of cultural formulation will give insight to not only the gov-
erning structure, but also to the governed.110  Ikemoto notes: 
“[C]ritical cultural inquiry is sensitive to multi-axis difference, dif-
ferential subordination, and the fact that ideology, including racial-
ized patriarchy, adapts quickly to structural changes.”111   
Structuralism theory is used by researchers to reveal issues in 
difference of treatment among the sexes; however, the theory rarely 
provides any inkling of recommendation as to how to correct the is-
sues it discovers.112  For example, if health disparities are attributed to 
race and gender separately and not under a holistic approach, women 
of color fall into one of two categories of this assumption: that they 
react to treatment the same way as the men in their particular race or 
that they will react to treatment a certain way based on research pri-
marily conducted on white women.113 
 Women of color are victimized on two levels.  The first is the 
standard biological discrimination, as addressed by the Agenda.114  
The second is their psychosocial demographic factors including their 
race and socioeconomic status.115  Women of color have health needs 
that desperately need to be addressed and it is imperative that they do 
not become a mere subcategory in race and gender studies.116 
 
 107. Id. 
 108. Id. 
 109. Id. at 1026. 
 110. Id. 
 111. Ikemoto, supra note 85, at 1026 (Ikemoto also discusses how this theory’s study of 
ideology allows for “a more nuanced and complicated understanding of how inequality 
becomes embedded in out understanding of [health].”). 
 112. Id. at 1050. 
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 114. See generally id. 
 115. See generally id. 
 116. See generally id. 
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iv. International Human Health Rights: HIV/AIDS Pandemic and 
Women 
 Another relatively new health concern is the rise of HIV/AIDS 
throughout the world.  “To curb the spread of the pandemic, [we] 
must focus on the structural and contextual determinants shaping the 
course of the pandemic, especially the social or traditional practices 
that violate women’s human rights and leave them more vulnerable to 
HIV/AIDS.”117  The HIV/AIDS pandemic is posing challenges to the 
international human rights of women throughout the world, primarily 
in developing countries.118  Spectar argues that HIV/AIDS has be-
come a global threat to the international human health rights for 
women and should be sparking the attention of national leaders 
around the world.119 
 There are numerous factors affecting the spread of HIV/AIDS 
among women, particularly in developing countries.120  In general, 
women are deemed to be powerless and of a lower status in develop-
ing countries.121 Under this generalization, women are much more 
vulnerable to become victims of sexual abuse and coercion.122  
Hence, women are far more likely to be pressured into a situation that 
presents an exposure to possible infection of HIV or other sexually 
transmitted diseases.123 
 Other prominent factors continuing the pandemic include “bar-
baric cultural practices” and domestic violence.124  Genital mutilation 
continues to occur in many areas around the world.125  During the 
mutilation process, women run the risk of contracting HIV and possi-
bly bleeding to death from subsequent injuries.126  Moreover, many 
 
 117. J.M. Spectar, The Hydra Hath but One Head: The Socio-Cultural Dimensions of the 
AIDs Epidemic & Women’s Right to Health, 21 B.C. THIRD WORLD L.J. 1, 2 (2001). 
 118. Id. at 3. 
 119. Id. (“In fact, the situation in developing countries is becoming increasingly grave—to 
a degree that AIDS is effectively an “aggressor” or a global threat to women’s interna-
tional human rights, particularly the right to health.”). 
 120. Id. at 4. 
 121. Spectar, supra note 117. 
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countries still view violence towards a woman as a man’s right.127  
Domestic violence “is a major socio-cultural condition that violated 
women’s human right to health.”128  In domestic violence situations, 
women are often in a position in which they cannot refuse sex and 
usually do not have the option of using any sort of sexual protec-
tion.129  These factors raise serious issues in the treatment of women.  
Women are not only thought to be second class citizens; they are also 
more likely to be exposed to abusive situations in which they have no 
control over what happens to their bodies.130 
 Many women in developing countries are afraid of the reper-
cussions should they report any sort of abuse.131  According to Spec-
tar, the legal systems of developing countries often side with abusers 
and further traumatize the victims.132  In fact, in many developing 
countries, both governing bodies and even family members discrimi-
nate against women with HIV/AIDS.133  There, women are often de-
nied jobs, housing, and healthcare.134   
 To achieve the goals of the Agenda worldwide, the treatment 
and view of women’s status throughout the world must be shifted.  
Women in developing countries are stigmatized as lesser beings.135  
The biopsychosocial stereotypes of women are the underlying issue 
in the lack of just treatment to women in healthcare. 
 This is not to say men’s medical treatment should be neglected 
or ignored, but merely that both research of men and women, of all 
races and ages, should be on a level playing field.  The goal of the 
women’s health initiatives should be to increase recognition of wom-
en’s health, without causing a complete neglect of men’s health re-
 
 127. Id. at 7 (It is important to note that domestic violence runs rampant through both de-
veloped and developing countries in different ways.). 
 128. Id. 
 129. Id. 
 130. See generally id. 
 131. Spectar, supra note 117, at 7. 
 132. Id. (“For example. In Tanzania, female rape victims who bring charges against their 
attackers are discriminated against to the extent that these women (but not their male 
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 134. Women with HIV/AIDS tend to be more stigmatized if they are monogamous wives.  
Their in-laws often blame these women for exposing their son and his fate.  Some-
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search.  The mindset must shift to recognize that men and women are 
biologically different, yet socially equal.  Modern medicine can use 
this knowledge to alter its practice accordingly in order to promote 
the healthiest population possible.  There are numerous ways re-
searchers can work towards this goal.   
b. Clinical Trials 
i. Varied Biological Responses 
 One of the key ways to advocate this issue is through changes 
in gender treatment of clinical trials.  It has been well established that 
biological reactions to medical treatments vary depending on the 
subgroup of humans being tested.136  A major concern in clinical tri-
als is what researchers call a “directional difference.”137  Directional 
differences occur in research outcomes when one trial group benefits 
from the treatment, while the other is harmed by the treatment.138   
 Jesse Berlin and Susan Ellenberg founnd there is no question 
that men and women respond differently to treatments and that the 
differences in response have hardly been studied and are relatively 
unknown.139  Berlin and Ellenberg attribute this lack of data primarily 
to the difference in genetics between men and women; “the broader 
issue really centers on the biological factors, possibly defined by 
genes or gene expression, that may directly or indirectly modify the 
effect of specific treatments on specific individuals.”140  
ii. Mental Health and Substance Abuse Trials 
 Mental Health is a rapidly growing concern in the modern 
world of medicine, and substance abuse is a growing trend among 
 
 136. Jesse A. Berlin & Susan S. Ellenberg, Inclusion of Women in Clinical Trials, 7 BMC 
MED. 1, 2 (2009). 
 137. Berlin & Ellenberg, supra note 136. 
 138. Id. Berlin and Ellenberg provide an example of a recent medication trial for a heart 
failure drug.  The medication was successful and effective on black test subjects and 
ineffective on white test subjects.  If men of different races and the (assumed) same 
biological make-up can react differently to a drug, then women can most definitely re-
act differently to drugs than men.  Id. 
 139. Id. at 3. 
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women.141  Shelly Greenfield found that women trying to enter sub-
stance abuse treatment face many barriers.142  They also found evi-
dence that women preferred participating in women-only, as opposed 
to mixed-gender, treatment programs.143  Women tended to perceive 
women-only treatment programs as safer and more comfortable envi-
ronments where they can focus on rehabilitation.144   Greenfield at-
tributes this perception to the fact that women and men have differed 
risk factors in substance abuse, including but not limited to medical 
consequences, reasons for relapse, and co-occurring mental disor-
ders.145   
 Upon thorough investigation, Greenfield  found there are no 
empirical studies on women-only treatment groups for substance 
abuse.146  “There is [no empirical research] of a manual-based recov-
ery group for women that is not specific for type of substance abuse, 
co-occurring psychiatric disorders, or stages of the lifecycle.”147  Nor 
were there any studies on generic recovery groups for women.148  
Greenfield found this to be disconcerting because the majority of 
substance abuse treatment is conducted in a group setting, so they 
conducted a comparative treatment between women-only substance 
abuse treatment groups and mixed-gender treatment groups to pro-
vide empirical data on women in a clinical group setting.149 
 Greenfield predicted that participants in the all-women test 
group would have higher rates of post-treatment satisfaction than the 
 
 141. Shelly F. Greenfield et al., The Women’s Recovery Group Study: A Stage I Trial of 
Women-Focused Group Therapy for Substance Use Disorders Versus Mixed-Gender 
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participants in the mixed-gender group.150  The research provided ev-
idence that participants in the all-women group reported significantly 
higher levels of satisfaction after treatment, supporting the hypothe-
sis.151  The study suggests that the participants of the all-women 
group were more satisfied due to enhanced satisfaction of the session 
content, as well as their overall experiences in the group process in an 
all-woman group.152  This could provide evidence that women may be 
more comfortable in clinical treatments without the inclusion of men, 
particularly in studies treating mental health diseases. 
 iii. Menopause and Hormone Therapy  
 Menopause, though a natural biological process, is not general-
ly an event women eagerly anticipate over the course of their lives.  
Around the 1900s, women were beginning to be offered pharmaceu-
tical options to suppress the symptoms of menopause, such as hot 
flashes and mood swings.153  These original forms of medications in-
cluded women ingesting extracts of other animals’ ovaries.154  Vari-
ous other hormone therapies were attempted throughout the 1960s, 
when the anti-menopause culture made a sociological shift.155 
 Starting in the 1960s, pharmaceutical hormone therapy became 
a mass produced answer to the prevention of menopause itself as op-
posed to suppression of the symptoms.156  Famous gynecologist Dr. 
Robert Wilson published the 1966 novel Feminine Forever in which 
he predicted that the use of pharmaceutical hormone replacement 
therapy could curb the effects of aging in women.157  Dr. Wilson be-
lieved that “[t]hrough hormone therapy, a woman could simulate the 
hormones of reproduction and thereby stay youthful and attractive 
 
 150. Greenfield et al., supra note 141 (“The initial hypothesis of this study was that more 
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throughout the lifespan.  All the right words were in place: youth, 
vigor, and sex.”158  Dr. Wilson understood the use of estrogen in 
hormone therapy was a way to stay youthful.159  He felt strongly that 
physical signs of aging, such as wrinkles, should be avoided.160 
 Dr. Wilson’s progressive answers to the crisis of aging opened 
the floodgates to the business of ending the aging process for wom-
en.161  By the early 1970s, hormone therapy had become a popular 
treatment among women throughout Western Europe and the United 
States.162 In the 1990s, NIH researchers completed a study on women 
who used hormone therapy in the 1970s—when it was first adminis-
tered to women with relatively little clinical trial research.163  Re-
searchers noticed a correlation between hormone use and the devel-
opment of breast cancer; concluding that the risk of breast cancer in-
increases with the frequency of hormone therapy.164  Around the 
same time, Great Britain also produced a study that followed 828,923 
post-menopausal women and found the same correlation as NIH.165 
 By 2002, NIH researchers found that the risks associated with 
women’s hormone therapy far exceeded the benefits.166  In 2004, after 
about forty years of administering a risky form of hormone therapy, 
researchers attempted to develop a safer form of hormone therapy for 
women.167  This attempt to find safer alternatives has been successful 
in modern medicine; however, researchers are continuing to find nu-
merous correlations between use of hormone therapy and increased 
risk of cancer.168 
 It is concerning that this pharmaceutical revolution was devel-
oped about fifty years ago based on an opinion by a male gynecol-
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 159. Id. 
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ogist trying to prevent the physical changes of menopause because 
the changes were deemed unbecoming.169  Aside from that, women 
were being treated with hormone therapy without clinical research 
regarding the risks and negative effects hormone therapy could cause.  
Women’s health initiatives are actively working to prevent admin-
istration of medical treatments that are not tested.  There are still 
many who critique the mission of women’s health initiatives. 
c. Criticisms of Women’s Health Initiatives and the Neglect 
of Men 
 According to Megan Veith, this shift to women’s health con-
cerns in the recent past has left developments in male health neglect-
ed.170  Veith concludes that men are instead the most discriminated 
against.171  She finds men to be far more burdened with illnesses than 
women throughout their lifespan, and this is reflected by their shorter 
projected lifespan.172  Veith argues that men are in much greater need 
of medical attention than women and that men’s health should really 
be the focus in modern medical treatment.173   
 She offers intensive research to support her conclusion that 
men are at a much higher risk of chronic disease and injury.174  Veith 
notes men lead much riskier lifestyles; they are more likely to engage 
in activities such as binge drinking alcohol, driving without a seat-
belt, and playing riskier sports.175  Veith argues that men’s sexual ac-
tivity is much riskier than women’s, yet she makes no counterargu-
ment in regards to instances against women in powerless situations, 
such as genital mutilation and domestic violence.176 She emphasizes 
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that men reported remarkably higher rates of syphilis and HIV.177  Fi-
nally Veith found, “men are also more likely than women to develop 
some forms of cancer including lung, colorectal, throat, stomach, 
pancreas, bladder, non-Hodgkin’s lymphoma and leukemia.”178 
It is entirely possible that resources have not been spread equally 
among gender-based medical treatments.  However, Veith fails to 
take a more holistic look at society.  There is little in response to the 
psychological and sociological treatment of women throughout the 
world.  She eloquently states, “a more progressive and beneficial way 
to look at gender and medicine is not to look to whether men or 
women are more entitled to healthcare, but to look at how medicine 
can be used to benefit both genders.”179 
 The purpose of this comment is not to present evidence to steer 
healthcare away from developing men’s health, but to ensure genders 
are recognized for their biological differences and thus seek the most 
optimum healthcare for all people throughout the world.  It is im-
portant to look at both genders as different biological beings in order 
to shape medical treatments to improve the lives of everyone.  This 
comment is meant to provide a holistic representation of women in 
society, how they are faced with different challenges and barriers 
than men, and how this affects women’s healthcare.  
IV. The Future for Women Around the World  
a.  Women and Health Initiative and a Global Perspective  
 It is imperative that all people around the world, no matter 
their biological sex, are provided with the best healthcare possible.  
The Agenda is working to accomplish well-rounded healthcare for all 
women.180  Through the primary collection of research on non-
reproductive chronic diseases in women and finding ways to include 
women in clinical trials, global public health will improve greatly. 
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 From the structuralism perspective, women have been treated 
as lesser citizens in the realm of medical research and clinical trials.  
Since the Thalidomide tragedy, the consideration to exclude women 
who are pregnant or are trying to get pregnant from clinical trials is 
understandable.  Clinical trials involve the risk of at least one human, 
and thus it is justifiable to exclude a person carrying an even more 
vulnerable person. The key problem, however, is that these medica-
tions, once approved in trials using men, are then administered to 
women.  This appears to be an even riskier way to test female re-
sponses to drugs. 
 Though reproductive protection is vital to the survival of man-
kind, it is not the only health risk for which women need protection.  
In fact, HIV/AIDS is currently the leading cause of death among 
women around the world between the ages of fifteen and forty-nine, 
followed by maternal complications.181  The third is self-harm and 
mental health disorders.182  Melinda Gates notes that women’s health 
is facing a fast-growing epidemic of chronic diseases among women, 
such as cancer, diabetes, and cardiovascular diseases, and that non-
communicable diseases are rapidly rising in rank.183   
 Gates states, “[t]hese findings raise important questions for 
government leaders, health experts, and parents.  How are underlying 
social detriments of women’s health affecting life options of girls and 
women?  Are government policies sufficiently focused on these criti-
cal stages in the life course to ensure that girls grow into healthy, 
productive women?”184  These important questions are what the 
Agenda seeks to answer. 
Throughout the world, options remain limited for women’s 
health.  This is attributed to biological, psychological, and sociologi-
cal factors often barring equal access to women’s healthcare.  The 
Agenda seeks to understand how women fit into society, not simply 
as reproductive beings.185  Richard Horton and Audrey Ceschia are 
hopeful that modern globalization is shrinking the gaps of inequality 
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between countries.186  However, they are fearful that globalization has 
aggravated inequalities within countries.187  With increased commu-
nication and travel, all countries have been pulled into the limelight 
and are being watched by their fellow countries.188  Globalization has 
produced social tensions that are negatively affecting the stability of 
societies.189  Treatment outside of direct biological needs can raise the 
esteem of women, thus preventing mental health issues and improv-
ing overall physical health.190   
 At the most primitive, without healthy women, there is an un-
sustainable society.  If women’s health is neglected around the world, 
then as a society, about half of the world’s population is being ne-
glected.191  In both Western society and developing countries, lack of 
healthcare feeds into endless cycles of poverty and violence.192   
b.  The Future for Gender and Medicine 
 There is hope for the future of gender and medicine.  “Western 
society has seen women gain the right to vote, receive higher educa-
tion, and continue on to careers in similar positions of authority as 
their male counterparts.  Thus…why would something so fundamen-
tal and essential as women’s health continue to be constrained by 
male-oriented and male-dominated clinical trials?”193 
  There may be critics to the shift of focusing on women’s 
health, and though some arguments have merit, it is not a battle to 
eliminate male healthcare research.  The key to a well-balanced 
healthcare system is to treat every person in the best and safest way 
possible.  Numerous trials have provided evidence that recognizes the 
need for distinguishing effects based on gender.  
 Chronic and non-communicable diseases are on the rise among 
the female population.  In a study produced by Niewada in Warsaw, 
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Poland, the researchers studied over 17,000 stroke patients.194  Their 
conclusion stressed the differences in reactions between the male and 
female patients and that “further research to explore the underlying 
biological mechanism is justified [to] improve [health] outcomes of 
female patients.”195  Around the world, medical researchers are find-
ing differences between genders, which will hopefully be implement-
ed in future medical treatments and clinical trials.  The question of 
including pregnant women in clinical trials continues to be addressed 
by researchers and will likely be an ethical dilemma addressed in the 
foreseeable future.196 
 There have been numerous laws enacted by governments to 
protect vulnerable populations such as prisoners, children, and preg-
nant women.197  According to Barbara Noah, the research culture is 
very much against the inclusion of pregnant women.198  However, 
there have been great strides in clinical trials towards women and this 
mentality may change.  Some have suggested that when there is a po-
tential risk to the fetus in a clinical trial, consent from both the moth-
er and father should be required to create a fail-safe system for the re-
search liability.199  Over the past decade, numerous arguments have 
been presented in favor of including women who are pregnant or can 
become pregnant in trials.200  To develop further understanding of the 
overall health of women, the inclusion of this population, while risky, 
could continue to close the discrimination gap being fought by the 
Agenda. 
 The future for gender recognition is seemingly positive.  There 
are still health concerns for women, but history has shown quite a 
shift in the past fifty years in regard to the treatment of women in at 
least Western society.  For developing countries, this may unfortu-
nately take quite a bit longer.  The Agenda will continue to close this 
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gap in treatment.  It is an essential human right to all people to bene-
fit from global health developments. 
V.  Conclusion 
 The Agenda will hopefully improve the global health of wom-
en.  Their mission is to better understand the biology of women and 
how it differs from the biology of men.  There is a great deal of evi-
dence suggesting that there are marked differences between the sexes 
and they produce differed reactions to treatment.  As the new health 
agenda continues advocating against the discrimination of women, 
global health will improve. 
 History has shown that women have not had their needs met to 
the extent that men have in the realm of healthcare around the world.  
In the twenty-first century, it is time to change the conversation.  The 
improvement of global health is not only a moral duty in order to 
grant this essential human right, but a way to work towards ending 
worldwide poverty and crime.  For survival, health is a fundamental 
need—not only for women, but for mankind in general.  All people 
deserve to have that need met.  The New Women’s Health Agenda 
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